H&R GmbH & Co. KGaA / DE000A2E4T77

Press Release H&R GmbH & Co. KGaA confirms Figures for First Half-Year 2025 Sales revenues reach EUR 653.1 million EBITDA at EUR 40.1 million slightly below previous year Guidance for 2025 adapted Salzbergen, Germany, August 15, 2025. H&R GmbH & Co. KGaA (H&R KGaA for short; ISIN DE000A2E4T77) achieved consolidated operating earnings (EBITDA – consolidated earnings before income taxes, other financial income and expenses, depreciation, amortization, and impairment losses on intangible assets and property, plant, and equipment) of EUR 40.1 million at the end of the first half of 2025 (first half of 2024: EUR 41.1 million). EBIT amounted to EUR 10.9 million (first half of 2024: EUR 11.7 million). Consolidated earnings attributable to shareholders closed at EUR 0.3 million (first half of 2024: EUR 2.8 million). H&R KGaA thus generated earnings per share of EUR 0.01. Revenue declined in the first half of 2025, reaching EUR 653.1 million (first half of 2024: EUR 675.6 million). Overview of key figures:

in EUR million	HY1-2025	HY1-2024	Diff. abs.
Sales revenues	653.1	675.6	-22.5
ChemPharm REFINING	405.9	417.0	-11.1
ChemPharm SALES	237.1	243.6	-6.5
PLASTICS	18.9	24.2	-5.3
Consolidation	-8.7	-9.2	0.5
Operating earnings (EBITDA)	40.1	41.1	-1.0
ChemPharm REFINING	26.9	20.6	6.3
ChemPharm SALES	17.8	21.1	-3.3
PLASTICS	-1.9	1.2	-3.1
Consolidation	-2.7	-1.8	-0.9
EBIT	10.9	11.7	-0.8
EBT	4.9	5.3	-0.4
Consolidated income attributable to shareholders	0.3	2.8	-2.5
Consolidated income per share (in EUR)	0.01	0.07	-0.06
Cash flow from operating activities	24.6	5.5	19.1
Free Cash flow	5.1	-18.5	23.6
	Q2-2025	Q2-2024	Diff. abs.
Sales revenues	307.3	338.6	-31.3
ChemPharm REFINING	188.5	210.6	-22.1
ChemPharm SALES	113.4	120.7	-7.3
PLASTICS	9.2	11.9	-2.7
Consolidation	-3.8	-4.6	0.8
Operating earnings (EBITDA)	17.8	19.8	-2.0
ChemPharm REFINING	13.0	10.1	2.9
ChemPharm SALES	8.1	10.1	-2.0
PLASTICS	-1.5	0.8	-2.3
Consolidation	-1.8	-1.2	-0.6
EBIT	3.1	4.9	-1.8
EBT	0.2	1.7	-1.5
Consolidated income attributable to shareholders	-1.6	1.3	-2.9
Consolidated income per share (in EUR)	-0.04	0.03	-0.07
Cash flow from operating activities	32.7	-5.9	38.6
Free Cash flow	22.8	-18.3	41.1
	30/06/2025	31/12/2024	Diff. abs.
Balance sheet total	972.0	1.014,8	-42.8
Equity	449.9	468.6	-18.7
Eequity ratio (in %. differences in percentage points)	46.3	46.2	0.1

  As a result, we are currently on a course that makes an adjustment of the expected range to €77.0 million to €90.0 million seem reasonable. For detailed information on current and future business and earnings developments, the company refers to the half-year report as of June 30, 2025, published today, which is available for download at www.hur.com in the “Publications” section of H&R KGaA. Contact information: H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser Neuenkirchener Strasse 8, 48499 Salzbergen Tel.: +49 40 43218-321, Fax: +49 40 43218-390 e-mail: ties.kaiser@hur.com ; www.hur.com   H&R GmbH & Co. KGaA: H&R KGaA is a specialty-chemicals company listed on the Frankfurt Stock Exchange's Prime Standard segment. It develops and manufactures crude-oil-based chemical and pharmaceutical specialty products and produces high-precision plastic parts. Forward-looking statements and forecasts: This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.